CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eagle Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eagle Pharmaceuticals Inc
50 Tice Boulevard, Suite 315
Phone: (201) 326-5300p:201 326-5300 WOODCLIFF LAKE, NJ  07677  United States Ticker: EGRXEGRX
On December 12, 2023, the Audit Committee of the Board of Directors of Eagle Pharmaceuticals, Inc., based on the recommendation of, and after consultation with, the company’s management concluded that the previously issued unaudited interim condensed consolidated financial statements for the quarter ended June 30, 2023 should no longer be relied upon. During its review, the Company discovered that reserves recorded in its financial statements for the quarter ended June 30, 2023 primarily relating to returns and price adjustments for PEMFEXY® did not reflect certain information that should have been considered at the time.
Business Summary
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Executive Chairman of the Board, Interim Principal Executive Officer MichaelGraves 60 11/27/2023 11/1/2013
Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer Steven B.Ratoff 80 3/8/2024 3/1/2007
Independent Director LucianaBorio 52 4/28/2021 4/28/2021
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Acacia Pharma Ltd Royston Road, Duxford CAMBRIDGE United Kingdom
Acacia Pharma Group PLC The Officers Mess Business Centre CAMBRIDGE United Kingdom
Acacia Pharma Limited The Officers Mess Business Centre Duxford CAMBRIDGE United Kingdom

Business Names
Business Name
Acacia Pharma Group plc
Acacia Pharma Inc
Acacia Pharma Limited
Eagle Biologics, Inc.
Eagle Research Lab Limited
EGRX

General Information
Number of Employees: 134 (As of 12/31/2022)
Outstanding Shares: 12,986,971 (As of 8/1/2023)
Shareholders: 2
Stock Exchange: NASD
Federal Tax Id: 208179278
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024